Pulmonary Drug Delivery Systems Market: By Product Type (Metered Dose Inhaler, Nebulizer, Dry Powder Inhaler), By Technology (Manually Operated Inhalers, Digitally Operated Inhalers), By Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Arterial Hypertension, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Pulmonary Drug Delivery Systems Market size was valued at USD 52,670.16 million in 2022. It is expected to reach a value of USD 78,156.36 million by 2029, growing at a CAGR of 5.8% from 2023-2029. Pulmonary drug delivery systems help to treat diseases such as asthma, and cystic fibrosis. The pulmonary route is used in the treatment of various respiratory disorders. Pulmonary drug delivery is gaining popularity owing to its target specificity.

The pulmonary drug delivery system delivers the medication through the respiratory tract. It is majorly used in the treatment of conditions such as delivery of locally acting drugs directly to the sites of action. In December 2017, Sunovion receives the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Lonhala Magnair (glycopyrrolate) Inhalation Solution, also known as SUN-101/eFlow, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Industry trends in the market are evolving, which will aid players in developing successful long-term strategies. Both established and emerging markets have implemented business growth techniques. COVID-19 is an unprecedented worldwide public health crisis that has impacted practically every business, and its long-term repercussions are expected to have an influence on industry growth during the projection period. Our continuous study is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included. The research examines COVID-19 in light of changes in consumer behavior and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. Pulmonary Drug Delivery Systems Market research report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.

Pulmonary Drug Delivery Systems Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Pulmonary Drug Delivery Systems Market Dynamics

Increase in the prevalence of various chronic disease such as chronic pulmonary disease, tuberculosis, and bronchitis are expected to fuel the growth of pulmonary drug delivery systems market. The preference of the non-invasive techniques are witnessing to the growth of market. The minimum dosage requirement is another factor, which creates demand for pulmonary drug delivery systems market. The technological advancements, growing support from the government and non-government organizations, increasing awareness and rising funds are expected to anticipate the growth of the market. However, the government regulatory issues in the approval of the product would hamper the growth of pulmonary drug delivery systems market.

Pulmonary Drug Delivery Systems Market Segmentation

By Product Type
  • Metered Dose Inhaler
  • Nebulizer
  • Dry Powder Inhaler
By Technology
  • Manually Operated Inhalers
  • Digitally Operated Inhalers
By Disease Indication
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Pulmonary Arterial Hypertension
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The pulmonary drug delivery systems market size was valued at USD 52,670.16 million in 2022

The pulmonary drug delivery systems market key players are: Sunovion Pharmaceuticals Inc. (U.S) AstraZeneca plc (U.K) Omron Corporation (Japan) Novartis AG (Switzerland) Teva Pharmaceutical Industries Ltd. (Israel) GlaxoSmithKline (U.K) 3M (U.S) Boehringer Ingelheim GmbH (Germany)

The pulmonary drug delivery systems market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1. Executive Summary
2. Global Pulmonary Drug Delivery Systems Market Introduction 
2.1.Global Pulmonary Drug Delivery Systems Market  - Taxonomy
2.2.Global Pulmonary Drug Delivery Systems Market  - Definitions
2.2.1.Product Type 
2.2.2.Technology
2.2.3.Disease Indication
2.2.4.Distribution Channel
2.2.5.Region
3. Global Pulmonary Drug Delivery Systems Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Pulmonary Drug Delivery Systems Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Pulmonary Drug Delivery Systems Market  By Product Type , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Metered Dose Inhaler
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Nebulizer
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Dry Powder Inhaler
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Pulmonary Drug Delivery Systems Market  By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Manually Operated Inhalers
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Digitally Operated Inhalers
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Global Pulmonary Drug Delivery Systems Market  By Disease Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Asthma
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Chronic Obstructive Pulmonary Disease (COPD)
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Pulmonary Arterial Hypertension
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8. Global Pulmonary Drug Delivery Systems Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Online Pharmacies
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
9. Global Pulmonary Drug Delivery Systems Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10. North America Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Product Type  Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Metered Dose Inhaler
10.1.2.Nebulizer
10.1.3.Dry Powder Inhaler
10.2.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Manually Operated Inhalers
10.2.2.Digitally Operated Inhalers
10.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Asthma
10.3.2.Chronic Obstructive Pulmonary Disease (COPD)
10.3.3.Pulmonary Arterial Hypertension
10.3.4.Others
10.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospital Pharmacies
10.4.2.Retail Pharmacies
10.4.3.Online Pharmacies
10.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11. Europe Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Metered Dose Inhaler
11.1.2.Nebulizer
11.1.3.Dry Powder Inhaler
11.2.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Manually Operated Inhalers
11.2.2.Digitally Operated Inhalers
11.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Asthma
11.3.2.Chronic Obstructive Pulmonary Disease (COPD)
11.3.3.Pulmonary Arterial Hypertension
11.3.4.Others
11.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospital Pharmacies
11.4.2.Retail Pharmacies
11.4.3.Online Pharmacies
11.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12. Asia Pacific (APAC) Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Metered Dose Inhaler
12.1.2.Nebulizer
12.1.3.Dry Powder Inhaler
12.2.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Manually Operated Inhalers
12.2.2.Digitally Operated Inhalers
12.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Asthma
12.3.2.Chronic Obstructive Pulmonary Disease (COPD)
12.3.3.Pulmonary Arterial Hypertension
12.3.4.Others
12.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospital Pharmacies
12.4.2.Retail Pharmacies
12.4.3.Online Pharmacies
12.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13. Middle East and Africa (MEA) Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Metered Dose Inhaler
13.1.2.Nebulizer
13.1.3.Dry Powder Inhaler
13.2.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Manually Operated Inhalers
13.2.2.Digitally Operated Inhalers
13.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Asthma
13.3.2.Chronic Obstructive Pulmonary Disease (COPD)
13.3.3.Pulmonary Arterial Hypertension
13.3.4.Others
13.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospital Pharmacies
13.4.2.Retail Pharmacies
13.4.3.Online Pharmacies
13.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14. Latin America Pulmonary Drug Delivery Systems Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
14.1. Product Type  Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Metered Dose Inhaler
14.1.2.Nebulizer
14.1.3.Dry Powder Inhaler
14.2.  Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Manually Operated Inhalers
14.2.2.Digitally Operated Inhalers
14.3.  Disease Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Asthma
14.3.2.Chronic Obstructive Pulmonary Disease (COPD)
14.3.3.Pulmonary Arterial Hypertension
14.3.4.Others
14.4.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospital Pharmacies
14.4.2.Retail Pharmacies
14.4.3.Online Pharmacies
14.5.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Sunovion Pharmaceuticals Inc. (U.S)
15.2.2.AstraZeneca plc (U.K)
15.2.3.Omron Corporation (Japan)
15.2.4.Novartis AG (Switzerland)
15.2.5.Teva Pharmaceutical Industries Ltd. (Israel)
15.2.6.GlaxoSmithKline (U.K)
15.2.7.3M (U.S)
15.2.8.Boehringer Ingelheim GmbH (Germany)
16. Research Methodology 
17. Appendix and Abbreviations 
  • Sunovion Pharmaceuticals Inc. (U.S)
  • AstraZeneca plc (U.K)
  • Omron Corporation (Japan)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline (U.K)
  • 3M (U.S)
  • Boehringer Ingelheim GmbH (Germany)

Adjacent Markets